The discovery and development of romidepsin for the treatment of T-cell lymphoma

P Smolewski, T Robak - Expert opinion on drug discovery, 2017 - Taylor & Francis
Introduction: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).
It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a …
被引用次数：74 相关文章

The discovery and development of romidepsin for the treatment of T-cell lymphoma

P Smolewski, T Robak - Expert opinion on drug discovery, 2017 - pubmed.ncbi.nlm.nih.gov
Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi). It is also the
only bicyclic inhibitor to undergo clinical assessment and is considered a promising drug for …

The discovery and development of romidepsin for the treatment of T-cell lymphoma.

P Smolewski, T Robak - Expert Opinion on Drug Discovery, 2017 - europepmc.org
Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi). It is also the
only bicyclic inhibitor to undergo clinical assessment and is considered a promising drug for …